Stocks · News reference
This Agomab Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Analysts change outlook on top names. See all rating changes, including upgrades/downgrades/initiations. Coverage initiated on various stocks.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Agomab Therapeutics To Present Open-Label Extension Data For Ontunisertib In Fibrostenosing Crohn's Disease At UEG Week On October 20
Agomab Therapeutics Experimental Drug Delivers Sustained Disease Control in Long-Term Crohn's Disease Trial
Agomab Therapeutics reports positive 48-week Phase 2a trial data for ontunisertib in patients with fibrostenotic Crohn's disease.
Agomab Therapeutics Announces Results From 48-Week OLE Portion Of Its Phase 2A STENOVA Trial Evaluating Ontunisertib In Patients With Severe Crohn's Disease; Favorable Safety And Tolerability Profile Maintained Through Up To 60 Weeks Of Treatment; Low Annualized FSCD-Related Event Rate Of 3%
8-K filing — Apnimed, Inc. (APMD)
Filed: 2026-09-08 AccNo: 0001193125-26-385355 Size: 619 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Apnimed Q2 EPS $3.91 Beats $(0.34) Estimate, Sales $12.080M